Orion Portfolio Solutions LLC Reduces Stock Position in GSK plc (NYSE:GSK)

Orion Portfolio Solutions LLC cut its stake in GSK plc (NYSE:GSKFree Report) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,345 shares of the pharmaceutical company’s stock after selling 1,486 shares during the period. Orion Portfolio Solutions LLC’s holdings in GSK were worth $648,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc increased its stake in shares of GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares in the last quarter. BKM Wealth Management LLC acquired a new stake in GSK during the fourth quarter worth approximately $32,000. Jones Financial Companies Lllp boosted its position in GSK by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after acquiring an additional 509 shares during the last quarter. Princeton Global Asset Management LLC boosted its position in GSK by 54.3% during the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after acquiring an additional 533 shares during the last quarter. Finally, Armstrong Advisory Group Inc. boosted its position in GSK by 189.1% during the fourth quarter. Armstrong Advisory Group Inc. now owns 1,619 shares of the pharmaceutical company’s stock worth $60,000 after acquiring an additional 1,059 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GSK has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Check Out Our Latest Research Report on GSK

GSK Stock Performance

NYSE:GSK opened at $41.98 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $87.00 billion, a price-to-earnings ratio of 15.21, a PEG ratio of 1.24 and a beta of 0.66. The firm’s fifty day simple moving average is $42.67 and its 200 day simple moving average is $40.65. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92.

GSK (NYSE:GSKGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The firm had revenue of $9.34 billion for the quarter, compared to the consensus estimate of $8.98 billion. As a group, equities research analysts expect that GSK plc will post 4.11 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.58%. GSK’s payout ratio is 53.26%.

GSK Company Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Further Reading

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.